Objectives Excessive exposure to acetaminophen (APAP, paracetamol) can cause liver injury through formation of a reactive metabolite that depletes hepatic glutathione and causes hepatocellular oxidative stress and damage. Generation of this metabolite is mediated by Cytochrome-P450 (CYP) isoforms, mainly CYP2E1. A number of naturally occurring flavonoids can mitigate APAP-induced hepatotoxicity in experimental animal models. Our objective was to determine the mechanism of these protective effects and to evaluate possible human applicability. Methods Two flavonoids, luteolin and quercetin, were evaluated as potential inhibitors of eight human CYP isoforms, of six UDP-glucuronosyltransferase (UGT) isoforms and of APAP glucuronidation and sulfation. The experimental model was based on in-vitro metabolism by human liver microsomes, using isoform-specific substrates. Key findings Luteolin and quercetin inhibited human CYP isoforms to varying degrees, with greatest potency towards CYP1A2 and CYP2C8. However, 50% inhibitory concentrations (IC 50 values) were generally in the micromolar range. UGT isoforms were minimally inhibited. Both luteolin and quercetin inhibited APAP sulfation but not glucuronidation. Conclusions Inhibition of human CYP activity by luteolin and quercetin occurred with IC 50 values exceeding customary in-vivo human exposure with tolerable supplemental doses of these compounds. The findings indicate that luteolin and quercetin are not likely to be of clinical value for preventing or treating APAP-induced hepatotoxicity.
Introduction
Acetaminophen-induced hepatotoxicity is the leading cause of acute liver failure in the United States. [1] The key mechanism in APAP-induced hepatotoxicity is the CYP450-catalysed formation of the reactive metabolite, NAPQI, which depletes hepatic glutathione and accumulates to cause liver damage. [2] Approximately 5-9% of an orally administered APAP is metabolized by the CYP450-dependent oxidation pathways. CYP3A4, [3, 4] CYP2E1, [3, 5] CYP1A2, [6] CYP2D6 [7] and CYP2A6 [8] are involved in the formation of NAPQI. Parallel to the CYP450-dependent oxidation, the majority of an orally administered dose of APAP is metabolized by glucuronidation (about two-thirds) and sulfation (about one-third). Both of these metabolic pathways produce non-toxic conjugates. UGT1A1, UGT1A6, UGT1A9 and UGT2B15 are important UGTs involved in the glucuronidation of APAP. [9] [10] [11] [12] SULT1A1, SULT1A3/4, SULT1E1 and SULT2A1 have been reported to be major contributors to APAP sulfation. [13] A number of compounds have been studied for their possible protective effects against APAP-induced hepatotoxicity in animal models as well as clinically. [14, 15] For an example, in a mouse study, simultaneous treatment of cimetidine at 75 mg/kg with APAP significantly increased the LD 50 of APAP. [16] Cimetidine inhibits CYP1A2, CYP2C9, CYP2D6 and CYP3A4 both in vitro and clinically. [17] Cimetidine also inhibits APAP glucuronidation in vitro, but with a K i value 10-fold higher than for CYP450-dependent oxidation. [18] Therefore, the protective effects of cimetidine in mouse [16] may be due to its greater inhibition of the CYP450-dependent oxidation compared to glucuronidation. However, cimetidine did not protect against APAP-induced hepatotoxicity in humans, as the required exposure could not be achieved with tolerable doses. [15] Phytochemicals, such as flavonoids, in herbal extracts have protective effects on liver toxicity in experimental animals. [19] [20] [21] Although the protective effect is usually attributed to antioxidant activity, this has not been clearly established, in part because the diversity of phytochemicals in various herbs makes it difficult to identify the effective chemical components. [22] Flavonoids are widely distributed in edible plants such as fruits and vegetables. Quercetin (a flavonoid) is beneficial in alleviating APAP-induced hepatotoxicity in experimental animals. [19, 21] A study using a freshwater fish showed that the abnormalities associated with APAP exposure were reversed on treatment with celery extract, which contains flavonoids such as rutin, quercetin and luteolin. [20] The main goal of this study was to examine in vitro the inhibitory effects of luteolin and quercetin on the metabolic pathways of APAP, namely CYP-mediated oxidation, glucuronidation and sulfation, to investigate whether the flavonoids of interest have possible beneficial effects against APAP-induced hepatotoxicity. The study has the further objective of evaluating the extent to which protective effects in animal models can be attributed to metabolic effects of the flavonoids.
Materials and Methods

Materials and chemicals
Chemicals and solvents were purchased from SigmaAldrich Corp (St. Louis, MO, USA) or Fisher Scientific (Pittsburgh, PA, USA). Water was purified with a Milli-Q system (Millipore, MA, USA). Pooled human liver S9 was purchased from Celsis (Chicago, IL, USA).
In-vitro inhibition studies on CYP450-mediated oxidation and on glucuronidation using HLMs
The pooled HLMs used in this study contained a mixture of 53 individual human liver microsomes. Individual HLMs were prepared as previously described. [23, 24] Incubation procedures for the in-vitro inhibition studies on CYPmediated oxidation [23, 25, 26] and on glucuronidation [27, 28] were used, with modifications. Briefly, stock solutions of the index substrates were prepared in methanol at micromolar concentrations and stored at À20°C. [26] To evaluate the possibility of time-dependent inhibition, luteolin (or quercetin) was preincubated with the HLM proteins in the incubation mixtures at 37°C for 20 min. The preincubated contents (250 ll) were then transferred into the incubation tubes containing the index substrates for another timed incubation. Parallel incubations without preincubation were also conducted for comparison, as identification of increased inhibitory potency of inhibitors when the inhibitors are preincubated with HLMs and cofactors is consistent with mechanism-based or timedependent inhibition. The reactions were stopped by adding 100 ll of acetonitrile (or acidified acetonitrile with 85% H 3 PO 4 for CYP2B6 and CYP2C9) with an appropriate internal standard. After centrifugation, the supernatant was transferred to HPLC vials for HPLC-UV or HPLC-fluorescence analysis.
For the glucuronidation studies, luteolin (or quercetin) in concentrations of 0, 0.5, 2.5, 10, 50, 100 and 250 lM was added to separate tubes before evaporation of the solvent (methanol). The incubation mixture for glucuronidation contained 50 mM phosphate buffer (pH 7.5), 5 mM MgCl 2 , alamethicin at 50 ng per mg protein and an appropriate amount of the pooled HLMs (50-500 lg/ml). Mixtures were kept on ice for 5 min before use. The solution of UDPGA was prepared separately in phosphate buffer (50 mM, pH 7.5). Reactions were started by addition of UDPGA at a final concentration of 10 mM in the 100 ll incubation mixture. The incubations were carried out with or without a 20-min preincubation to evaluate whether the inhibition was time-dependent inhibition; 40 ll of acetonitrile (or acidified acetonitrile with 85% H 3 PO 4 for UGT2B7 and APAP glucuronidation) with internal standards was used to stop the reactions. After centrifugation, the supernatant was transferred to HPLC vials for HPLC-UV analysis.
Solvent effects of methanol and DMSO on human hepatic CYPs
The effects of methanol and DMSO on selected human CYP enzymes were investigated. Briefly, various percentages of methanol or DMSO (0, 0.05, 0.1, 0.5, 1 and 2% v/v) were introduced into the incubation mixtures containing specific index substrates. All incubations were performed in duplicate with pooled HLMs and without preincubation. Samples were incubated at 37°C for appropriate durations and stopped by an addition of 100 ll cold acetonitrile (in 250 ll of the incubation mixture) with internal standards. To minimize the solvent effects, controls containing the same percentages of methanol or DMSO as the incubation samples were used to normalize each sample.
In-vitro inhibition studies on APAP sulfation
The incubation procedures for APAP sulfation were based on previously published methods, with modifications. [29, 30] Briefly, APAP as the substrate was added to incubation tubes, and the solvent (methanol) was evaporated to dryness at 40°C under mild vacuum conditions. The concentration of APAP was 0.6 mM in the final volume of 100 ll. Luteolin at concentrations of 0, 0.025, 0.05, 0.1, 0.25, 0.5, 1, 2.5 and 10 lM and quercetin at concentrations of 0, 0.1, 0.5, 1, 2.5, 10, 50 and 100 lM were added to separate incubation tubes, and the solvent (methanol) was evaporated to dryness. One percent (v/v) methanol was then added to reconstitute luteolin (or quercetin). The incubation mixture for APAP sulfation was prepared with 50 mM phosphate buffer (pH 7.5), 5 mM MgCl 2 and 800 lg/ml pooled human S9. The PAPS cofactor solution (PAPS at 0.2 mM) was freshly prepared in water separately, prior to the incubation experiments. The reactions were started with an addition of the PAPS solution into the incubation mixture (100 ll). After 2-h incubation at 37°C, the reaction was stopped with 40 ll of acidified acetonitrile with 0.5% (v/v) of 85% H 3 PO 4 and with 3-AAP as the internal standard. After centrifugation, the supernatant was transferred to HPLC vials for HPLC-UV.
Analytical methods
In-vitro samples were analysed using previously described methods. [25, 26, 28] Representative HPLC chromatograms are shown in Figures S1-S15. APAP glucuronide and sulfate generated from the in-vitro incubations of APAP were analysed as reported previously. [26, 31] The software Chemstation (Agilent, Santa Clara, CA, USA) was used for integration and quantitation. 
Incubations with preincubation; b incubations without preincubation; c NC, not calculated (no IC 50 values were obtained due to <50% inhibition at the highest tested concentrations: 600 lM of luteolin and quercetin for the CYP systems and 250 lM of luteolin and quercetin for the UGT systems, respectively. The highest tested percentage for methanol and DMSO was 2%); d not tested; e APAP glucuronidation is a mixed effect of several UGT isoforms including UGT1A6, 1A1, 1A9 and 2B15; f APAP sulfation is a mixed effect of several SULT isoforms; g 52% inhibition at 250 lM. Table 1 .
Statistical methods
IC 50 values were determined by nonlinear regression analysis. The appropriate hyperbolic function was fitted to data points using SigmaPlot 11.0 (Systat Software, San Jose, CA, USA). These methods have been described in detail previously. [23, 26] Goodness of fit was validated by visual analysis and by R-square values. Additional statistical analysis was not undertaken, as no quantitative inferential judgements related to statistical comparisons of IC 50 values were needed in this study.
Results
IC 50 values of luteolin and quercetin
The in-vitro IC 50 values for luteolin and quercetin vs individual CYP and UGT enzymes in the pooled HLMs obtained from this study are summarized in Table 1 . Both luteolin and quercetin inhibited human hepatic CYP1A2, CYP3A, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1 (Figures 1 and 2 ) as well as UGT1A1 and UGT1A4 (Figure 3) , with various IC 50 values. Up to the highest tested concentrations of luteolin and quercetin (600 lM for the CYP systems and 250 lM for the UGT systems), IC 50 s for luteolin and quercetin vs UGT1A6, UGT1A9, UGT2B7 and UGT2B15 could not be calculated due to <50% inhibition ( Figure S16 ). For some of the substrate-inhibitor combinations, the preincubation procedure was associated with a reduction in the IC 50 values (or increased inhibitory potency) (Figures 1 and 2 ). This indicates the possibility of time-dependent inhibition (mechanism-based inhibition). [32, 33] However, the magnitude of reduction of IC 50 was modest at most.
In the studies using APAP as substrate, probenecid, the positive control inhibitor of APAP glucuronidation, yielded an IC 50 value of 0.5 mM. Luteolin and quercetin produced minimal inhibition of APAP glucuronidation (Figure 4 ). Table 1 . UGT, UDP-glucuronosyltransferase.
Both luteolin and quercetin were strong inhibitors of APAP sulfation, with IC 50 values of 1.1 and 3.5 lM, respectively ( Figure 5 ).
Solvent effects of methanol and DMSO on human hepatic CYPs
Organic solvents, namely methanol and DMSO, were used to reconstitute the flavonoids. Their effects on selected human CYP enzymes were thus investigated. Among the tested human CYP450 isoforms, CYP2E1 was the most sensitive to both methanol and DMSO. The IC 50 values for methanol and DMSO vs CYP2E1 were 0.63% and 0.06%, respectively. The IC 50 value for DMSO on CYP2C9 was 2.4%. CYP2B6 was also partially inhibited by 1% methanol (Table 1, Figure 6 and Figure S17 ).
Discussion
Flavonoids are important daily dietary constituents. Typical daily intake of five flavonoids in the United States, including quercetin, kaempferol, myricetin, apigenin and luteolin, was in the range of 20-22 mg. [34] In a Chinese university- Table 1 . HLM, human liver microsome.
Figure 5
In vitro inhibitory effects of (a) luteolin and (b) quercetin on acetaminophen sulfation. Data points represent the means AE standard errors (SEM) of each drug concentration that was tested in duplicate. IC 50 values were determined by nonlinear regression and summarized in Table 1 .
campus population, the daily consumption of luteolin was reported as around 8 AE 6 mg/day (Mean AE SD), with plasma concentrations of 101 AE 99 nmol/l. [35] Consumption of dietary supplements containing flavonoids in some populations can substantially increase the systemic exposure to flavonoids. In a study of daily supplementation of quercetin, the median maximum plasma concentrations of quercetin, including its glucuronidated and sulfated metabolites, were 431 nmol/l at 3 h after ingestion of 150 mg quercetin. [36] Concomitant administration of quercetin with APAP in rats (20 mg/kg, p.o. in normal saline, daily for 15 days) decreased the production of malondialdehyde, which is a by-product of lipid peroxidation indicating the presence of reactive oxygen species. Activity of antioxidant enzymes such as glutathione peroxidase, glutathione S-transferase, superoxide dismutase and catalase (in plasma, brain, lung, heart, liver, kidney and testes) and glutathione content (in lung, liver and kidney) was increased. [21] A study with freshwater fish showed that simultaneous exposure of celery leaf powder (500 mg/kg) with APAP for 24 h alleviated APAP-induced abnormities in tissue lipid peroxidation markers, tissue levels of enzymatic and non-enzymatic antioxidants, cellular thiol levels, the levels of hepatic electrolytes and abnormal liver histology. [20] Based on the outcome of these experimental animal studies, we conducted the in-vitro studies using human tissues (HLMs) in an attempt to evaluate the extent to which the findings could be applicable to humans.
Among CYP isoforms reported to be responsible for the NAPQI production, both luteolin and quercetin inhibited CYP1A2 and CYP3A in vitro, with IC 50 values <10 lM (Table 1 ). It is likely that both luteolin and quercetin could inhibit some component of the CYP-mediated oxidation of APAP by inhibiting CYP1A2 and 3A4 in vivo if the necessary concentrations could be achieved.
Because APAP glucuronidation and sulfation are major pathways of APAP clearance, we also tested whether luteolin or quercetin affect these metabolic pathways. Even though luteolin or quercetin inhibited several individual human hepatic UGTs at levels of 50 lM, they did not inhibit overall APAP glucuronidation (Figure 4) . We conclude that APAP glucuronidation is not likely to be inhibited by luteolin or quercetin at dietary levels. As for APAP sulfation, both luteolin and quercetin were strong inhibitors of that pathway ( Figure 5) .
The large discrepancy between low systemic exposures of flavonoids at dietary levels and the required high concentrations at the tissue sites to exert any potential effects leads to our conclusion in this study. Extrapolation of in-vitro findings to the in-vivo situation is not straightforward. Plasma concentrations of flavonoids are not equivalent to their concentrations at the sites of clinical activity. [37] For example, flavonoids such as luteolin and quercetin may be more concentrated in liver than in plasma. [38] Further, only the unconjugated forms of luteolin and quercetin were Table 1 . DMSO, dimethyl sulfoxide. studied in the in-vitro systems in this study. However, luteolin and quercetin are extensively transformed to glucuronide and sulfate conjugates as well to as methylated metabolites [39] in vivo. The reported in-vivo plasma concentrations of luteolin or quercetin usually include the conjugated and unconjugated forms due to the enzymatic hydrolysis steps commonly used in the sample preparation. In addition, the inhibitory effects of those major metabolites on hepatic metabolic enzymes have not yet been investigated. In any case, the in-vitro IC 50 values observed in this study in general are in the micromolar range, which is greater than reported in-vivo plasma concentrations which are in the nanomolar range.
The present study did not evaluate the selected flavonoids as a potential acute treatment for APAP-induced hepatotoxicity. Even if luteolin and quercetin did have hepatoprotective properties in cases of APAP overdose, the timing of the treatment relative to the time of overdose would be a critical factor. Most patients seek medical attenuation only after most of the drug is already metabolized, and the hepatotoxic damage cannot be reversed. [40, 41] At this point, any intervention that only affects drug metabolizing enzymes is unlikely to be efficacious.
In short, we used HLMs to examine the effects of luteolin and quercetin on APAP metabolism in vitro. The findings that luteolin or quercetin could inhibit some component of the CYP-mediated oxidation of APAP, and did not inhibit the APAP glucuronidation pathway, could explain the beneficial effects of luteolin and quercetin against APAPinduced hepatotoxicity observed in experimental animals. However, the observed IC 50 values for luteolin and quercetin in vitro substantially exceed usual systemic exposure in humans.
Conclusion
We investigated metabolic interactions between APAP and two flavonoids with in-vitro inhibition studies using HLMs and human liver S9. The inhibitory properties of the unconjugated and aglycone flavonoids, namely luteolin and quercetin, on common human hepatic CYP and UGT enzymes as well as on APAP metabolism were evaluated. In addition to antioxidant activity, we suggest that the beneficial effects of flavonoids (luteolin and quercetin) towards APAP-induced hepatotoxicity in experimental animals could also be explained by their inhibitory properties towards common human hepatic CYPs. However, we estimate that these protective effects in humans are not likely to occur at customary levels of exposure.
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Additional Supporting Information may be found in the online version of this article: Figure S1 . HPLC chromatogram of phenacetin (a CYP1A2 specific index) and its metabolite generated using HLMs (a) acetaminophen, (b) 2-acetaminophenol as the internal standard and c) phenacetin. Figure S2 . HPLC chromatogram of triazolam (a CYP3A specific index) and its metabolites generated using HLMs (a, b) a-hydroxytriazolam and 4-hydroxytriazolam as the triazolam metabolites formed by HLMs, (c) triazolam. Figure S3 . HPLC chromatogram of bupropion (a CYP2B6 specific index) and its metabolite generated using HLMs (a) 2-acetaminophenol as the IS, b) hydroxybupropion as the bupropion metabolite formed by HLMs and c) bupropion. Figure S4 . HPLC chromatogram of taxol (a CYP2C8 specific index) and its metabolite generated using HLMs (a) phenacetin as the IS (b) 6-hydroxytaxol as the taxol metabolite formed by HLMs, (c) taxol. Figure S5 . HPLC chromatogram of flurbiprofen (a CYP2C9 specific index) and its metabolite generated using HLMs (a) 4 0 -hydroxyflurbiprofen as the flurbiprofen metabolite formed by HLMs, (b) naproxen as the IS and (c) flurbiprofen. Figure S6 . HPLC chromatogram of s-mephenytoin (a CYP2C19 specific index) and its metabolite generated using HLMs (a) 4 0 -hydroxymephenytoin as the s-mephenytoin metabolite formed by HLMs, (b) phenacetin as the IS, (c) s-mephenytoin and (d) a case-specific peak of quercetin washout in this particular study. Figure S7 . HPLC chromatograms of dextromethorphan (a CYP2D6 specific index) and its metabolite generated using HLMs (a) dextrorphan as the dextromethorphan metabolite formed by HLMs, (b) pronethalol as the IS, and (c) dextromethorphan. Figure S8 . HPLC chromatograms of chlorzoxazone (a CYP2E1 specific index) and its metabolite generated using HLMs (a) 6-hydroxychlorozoxazone as the chlorzoxazone metabolite formed by HLMs, (b) phenacetin as the IS, and (c) chlorzoxazone. Figure S9 . HPLC chromatogram of the metabolites of b-Estradiol (a UGT1A1 index) generated using HLMs (a, c) estradiol-3-glucuronide and estradiol-17-glucuronide as the b-Estradiol metabolite formed by HLMs, and (b) phenacetin as the IS. Figure S10 . HPLC chromatogram of trifluoperazine (a UGT1A4 specific index) and its metabolite generated using HLMs (a) phenacetin as the IS, (b) trifluoperazine-glucuronide as the trifluoperazine metabolite formed by HLMs, and c) trifluoperazine. Figure S11 . HPLC chromatogram of serotonin (a UGT1A6 index) and its metabolite generated using HLMs (a) serotonin-glucuronide as the serotonin metabolite formed by HLMs, and (b) serotonin. Figure S12 . HPLC chromatogram of the metabolites of propofol (a UGT1A9 index) and its metabolite generated using HLMs (a) 3-acetaminophenol (3-AAP) as the IS, and (b) propofol-glucuronide as the propofol metabolite formed by HLMs. Figure S13 . HPLC chromatogram of 3 0 -azidothymidine (AZT) (a UGT2B7 index) and its metabolite AZT-glucuronide generated using HLMs, and 3-acetaminophenol as the IS. Figure S14 . HPLC chromatogram of oxazepam (a UGT2B15 specific index) and its metabolites, R-oxazepam glucuronide and S-oxazepam glucuronide, generated using HLMs, and 3-acetaminophenol (3-AAP) as the IS. Figure S16 . In vitro inhibitory effects of luteolin and quercetin on human hepatic (a) UGT1A1, (b) UGT1A4, (c) UGT1A6, (d) UGT1A9, (e) UGT2B7 and (f) UGT2B15. Figure S17 . Inhibitory effects of (a) methanol and (b) DMSO on human hepatic CYP enzymes in HLMs.
